rt-PA in Ischemic Stroke After Idarucizumab Administration rt-PA in Ischemic Stroke After Idarucizumab Administration
This case demonstrates that thrombolytic therapy with rt-PA after reversal of dabigatran with idarucizumab may be safe and feasible in patients with acute ischemic stroke with lacunar infarct.Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 4, 2020 Category: Consumer Health News Tags: Family Medicine/Primary Care Journal Article Source Type: news
Cost effectiveness of dabigatran: value of real-world data
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - October 31, 2019 Category: Drugs & Pharmacology Source Type: news
Medical News Today: Existing blood thinner delays Alzheimer's disease in mice
New research in mice suggests that dabigatran, a blood thinning drug, may help delay the development of Alzheimer's by maintaining normal brain blood flow. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - October 8, 2019 Category: Consumer Health News Tags: Alzheimer's / Dementia Source Type: news
Idarucizumab Reverses Dabigatran Regardless of Renal Function Idarucizumab Reverses Dabigatran Regardless of Renal Function
In a RE-VERSE AD subgroup analysis, idarucizumab reversed the effects of dabigatran in more than 98% of patients, regardless of renal function.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - October 1, 2019 Category: Neurology Tags: Cardiology News Source Type: news
RE-SPECT-CVT-Study-data-published
Results from RE-SPECT CVT ® published - first trial of NOAC in cerebral venous thrombosisStudy published in JAMA Neurology investigated Pradaxa ® (dabigatran etexilate) in patients with cerebral venous and dural sinus thrombosis (CVT)First exploratory study of a non-vitamin K antagonist oral anticoagulant (NOAC) in this populationThe study is part of Boehringer Ingelheim ’s commitment to advancing thrombosis care (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - September 4, 2019 Category: Research Source Type: news
dabigatran (Pradaxa)
Title: dabigatran (Pradaxa)Category: MedicationsCreated: 1/11/2016 12:00:00 AMLast Editorial Review: 9/3/2019 12:00:00 AM (Source: MedicineNet Heart General)
Source: MedicineNet Heart General - September 3, 2019 Category: Cardiology Source Type: news
RE-LY-trial-publication-10-year-anniversary
Anniversary of the pivotal RE-LY ® trial marks a decade of innovation for stroke prevention in AF patients10 years ago, RE-LY ® marked the first time a randomised trial showed that a non-vitamin K antagonist oral anticoagulant (NOAC) was safer and at least as effective as warfarin for stroke prevention in atrial fibrillation (SPAF)1-3First major scientific advancement in anticoagulation care in over fifty yearsOver 100,000 patients have been included in the RE-VOLUTION study programme worldwide,4 and research into dabigatran etexilate continues (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - August 30, 2019 Category: Research Source Type: news
Dabigatrans-safety-efficacy-confirmed-in-VTE-children
Dabigatran ’s safety and efficacy established for management of VTE in children First studies to assess treatment and prevention of recurrent venous thromboembolism (VTE) with dabigatran etexilate in children The Phase IIb/III DIVERSITY study demonstrated that the efficacy and safety profile of dabigatran was comparable to standard of care (SOC) for the treatment of children with acute VTE1A second Phase III study reinforced the safety profile in children with persistent VTE risk factors receiving dabigatran for prevention of recurrent VTE2 (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 9, 2019 Category: Research Source Type: news
Antithrombotic agents and traumatic brain injury in the elderly population: hemorrhage patterns and outcomes - Scotti P, S éguin C, Lo BWY, De Guise E, Troquet JM, Marcoux J.
OBJECTIVE: Among the elderly, use of antithrombotics (ATs), antiplatelets (APs; aspirin, clopidogrel), and/or anticoagulants (ACs; warfarin, direct oral ACs [DOACs; dabigatran, rivaroxaban, apixaban]) to prevent thromboembolic events must be carefully weig... (Source: SafetyLit)
Source: SafetyLit - July 8, 2019 Category: International Medicine & Public Health Tags: Age: Elder Adults Source Type: news
FDA Drug Safety Communication: Safety review of post-market reports of serious bleeding events with the anticoagulant Pradaxa (dabigatran etexilate mesylate)
(Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 26, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Use of Dabigatran With Antiretrovirals Use of Dabigatran With Antiretrovirals
Is concurrent treatment with dabigatran and antiretrovirals safe? Find out what there is to know about possible interactions between these drugs.HIV Medicine (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - May 20, 2019 Category: Infectious Diseases Tags: HIV/AIDS Journal Article Source Type: news
Pradaxa Fails to Prevent Recurrence After Cryptogenic Stroke Pradaxa Fails to Prevent Recurrence After Cryptogenic Stroke
Dabigatran, sold under the brand name Pradaxa by Boehringer Ingelheim to prevent stroke in people with atrial fibrillation, is no more effective than aspirin for preventing a subsequent stroke in patients who have experienced a cryptogenic stroke.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 16, 2019 Category: Consumer Health News Tags: Cardiology News Source Type: news
Dabigatran Doesn't Beat Aspirin for Preventing Recurrent Stroke
THURSDAY, May 16, 2019 -- Dabigatran is not superior to aspirin for preventing recurrent stroke in patients with recent history of embolic stroke of undetermined source, according to a study published in the May 16 issue of the New England Journal... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 16, 2019 Category: Pharmaceuticals Source Type: news
NOAC-vs-ASA-in-ESUS-trial-results-published-in-NEJM
Trial results of Pradaxa ® vs ASA in ESUS published in NEJMFirst Phase III randomised clinical trial to compare dabigatran etexilate and acetylsalicylic acid (ASA) No significant difference in recurrent stroke prevention after ESUSDabigatran showed no significant difference in major bleeding (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - May 16, 2019 Category: Research Source Type: news
Independent large real-world study comparing NOACs in AF-patients
The results from an independent retrospective comparative study, published in January 2019 in the American Journal of Medicine, showed that dabigatran was associated with a more favourable benefit-harm profile than both warfarin and rivaroxaban. (Source: World Pharma News)
Source: World Pharma News - April 16, 2019 Category: Pharmaceuticals Tags: Featured Boehringer Ingelheim Business and Industry Source Type: news
